Cancer biomarker (English Wikipedia)

Analysis of information sources in references of the Wikipedia article "Cancer biomarker" in English language version.

refsWebsite

Global rank English rank

92nih.gov

4^th place

69doi.org

2^nd place

10semanticscholar.org

11^th place

8^th place

6harvard.edu

18^th place

17^th place

3handle.net

102^nd place

76^th place

3web.archive.org

1^st place

2zenodo.org

621^st place

380^th place

1mlo-online.com

low place

1cancer.gov

1,684^th place

1,350^th place

1researchadvocacy.org

low place

1cshl.edu

low place

1time.com

61^st place

54^th place

1fda.gov

447^th place

338^th place

1cancer.org

3,680^th place

2,918^th place

1books.google.com

3^rd place

1singularityhub.com

low place

1worldcat.org

5^th place

books.google.com

Heinz-Josef Lenz (2012-09-18). Biomarkers in Oncology: Prediction and Prognosis. Springer Science & Business Media. p. 263. ISBN 978-1-4419-9754-8.

cancer.gov

"biomarker". NCI Dictionary of Cancer Terms. National Cancer Institute. 2011-02-02.

cancer.org

"Tumor Markers Fact Sheet" (PDF). American Cancer Society.

cshl.edu

repository.cshl.edu

Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, et al. (May 2004). "Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib" (PDF). The New England Journal of Medicine. 350 (21): 2129–2139. doi:10.1056/NEJMoa040938. PMID 15118073.

doi.org

Calzone KA (May 2012). "Genetic biomarkers of cancer risk". Seminars in Oncology Nursing. 28 (2): 122–128. doi:10.1016/j.soncn.2012.03.007. PMC 10433658. PMID 22542320.
Herceg Z, Hainaut P (June 2007). "Genetic and epigenetic alterations as biomarkers for cancer detection, diagnosis and prognosis". Molecular Oncology. 1 (1): 26–41. doi:10.1016/j.molonc.2007.01.004. PMC 5543860. PMID 19383285.
Li D, Chan DW (April 2014). "Proteomic cancer biomarkers from discovery to approval: it's worth the effort". Expert Review of Proteomics. 11 (2): 135–136. doi:10.1586/14789450.2014.897614. PMC 4079106. PMID 24646122.
Aizpurua-Olaizola O, Toraño JS, Falcon-Perez JM, Williams C, Reichardt N, Boons GJ (2018). "Mass spectrometry for glycan biomarker discovery". TrAC Trends in Analytical Chemistry. 100: 7–14. doi:10.1016/j.trac.2017.12.015. hdl:1874/364403.
Mishra A, Verma M (March 2010). "Cancer biomarkers: are we ready for the prime time?". Cancers. 2 (1): 190–208. doi:10.3390/cancers2010190. PMC 3827599. PMID 24281040.
Behne T, Copur MS (1 January 2012). "Biomarkers for hepatocellular carcinoma". International Journal of Hepatology. 2012: 859076. doi:10.1155/2012/859076. PMC 3357951. PMID 22655201.
Musolino A, Bella MA, Bortesi B, Michiara M, Naldi N, Zanelli P, et al. (June 2007). "BRCA mutations, molecular markers, and clinical variables in early-onset breast cancer: a population-based study". Breast. 16 (3): 280–292. doi:10.1016/j.breast.2006.12.003. hdl:11381/1629553. PMID 17257844.
Dienstmann R, Tabernero J (March 2011). "BRAF as a target for cancer therapy". Anti-Cancer Agents in Medicinal Chemistry. 11 (3): 285–295. doi:10.2174/187152011795347469. PMID 21426297.
Lamparella N, Barochia A, Almokadem S (2013). "Impact of Genetic Markers on Treatment of Non-small Cell Lung Cancer". Impact of Genetic Targets on Cancer Therapy. Advances in Experimental Medicine and Biology. Vol. 779. pp. 145–164. doi:10.1007/978-1-4614-6176-0_6. ISBN 978-1-4614-6175-3. PMID 23288638.
Orphanos G, Kountourakis P (2012). "Targeting the HER2 receptor in metastatic breast cancer". Hematology/Oncology and Stem Cell Therapy. 5 (3): 127–137. doi:10.5144/1658-3876.2012.127. PMID 23095788.
Deprimo SE, Huang X, Blackstein ME, Garrett CR, Harmon CS, Schöffski P, et al. (September 2009). "Circulating levels of soluble KIT serve as a biomarker for clinical outcome in gastrointestinal stromal tumor patients receiving sunitinib following imatinib failure". Clinical Cancer Research. 15 (18): 5869–5877. doi:10.1158/1078-0432.CCR-08-2480. PMC 3500590. PMID 19737953.
Kruijff S, Hoekstra HJ (April 2012). "The current status of S-100B as a biomarker in melanoma". European Journal of Surgical Oncology. 38 (4): 281–285. doi:10.1016/j.ejso.2011.12.005. PMID 22240030.
Ludwig JA, Weinstein JN (November 2005). "Biomarkers in cancer staging, prognosis and treatment selection". Nature Reviews. Cancer. 5 (11): 845–856. doi:10.1038/nrc1739. PMID 16239904. S2CID 25540232.
Wang Q, Chaerkady R, Wu J, Hwang HJ, Papadopoulos N, Kopelovich L, et al. (February 2011). "Mutant proteins as cancer-specific biomarkers". Proceedings of the National Academy of Sciences of the United States of America. 108 (6): 2444–2449. Bibcode:2011PNAS..108.2444W. doi:10.1073/pnas.1019203108. PMC 3038743. PMID 21248225.
Li X, Ye M, Zhang W, Tan D, Jaffrezic-Renault N, Yang X, Guo Z (February 2019). "Liquid biopsy of circulating tumor DNA and biosensor applications". Biosensors & Bioelectronics. 126: 596–607. doi:10.1016/j.bios.2018.11.037. PMID 30502682. S2CID 56479882.
Verma M, Manne U (October 2006). "Genetic and epigenetic biomarkers in cancer diagnosis and identifying high risk populations". Critical Reviews in Oncology/Hematology. 60 (1): 9–18. doi:10.1016/j.critrevonc.2006.04.002. PMID 16829121.
Leong PP, Rezai B, Koch WM, Reed A, Eisele D, Lee DJ, et al. (July 1998). "Distinguishing second primary tumors from lung metastases in patients with head and neck squamous cell carcinoma". Journal of the National Cancer Institute. 90 (13): 972–977. doi:10.1093/jnci/90.13.972. PMID 9665144.
Lapin M, Oltedal S, Tjensvoll K, Buhl T, Smaaland R, Garresori H, et al. (November 2018). "Fragment size and level of cell-free DNA provide prognostic information in patients with advanced pancreatic cancer". Journal of Translational Medicine. 16 (1): 300. doi:10.1186/s12967-018-1677-2. PMC 6218961. PMID 30400802.
Dragani TA, Matarese V, Colombo F (April 2020). "Biomarkers for Early Cancer Diagnosis: Prospects for Success through the Lens of Tumor Genetics". BioEssays. 42 (4): e1900122. doi:10.1002/bies.201900122. PMID 32128843. S2CID 212406467.
Terpos E, Dimopoulos MA, Shrivastava V, Leitzel K, Christoulas D, Migkou M, et al. (March 2010). "High levels of serum TIMP-1 correlate with advanced disease and predict for poor survival in patients with multiple myeloma treated with novel agents". Leukemia Research. 34 (3): 399–402. doi:10.1016/j.leukres.2009.08.035. PMID 19781774.
Kuukasjärvi T, Kononen J, Helin H, Holli K, Isola J (September 1996). "Loss of estrogen receptor in recurrent breast cancer is associated with poor response to endocrine therapy". Journal of Clinical Oncology. 14 (9): 2584–2589. doi:10.1200/jco.1996.14.9.2584. PMID 8823339.
Harris L, Fritsche H, Mennel R, Norton L, Ravdin P, Taube S, et al. (November 2007). "American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer". Journal of Clinical Oncology. 25 (33): 5287–5312. doi:10.1200/JCO.2007.14.2364. PMID 17954709.
Kröger N, Milde-Langosch K, Riethdorf S, Schmoor C, Schumacher M, Zander AR, Löning T (January 2006). "Prognostic and predictive effects of immunohistochemical factors in high-risk primary breast cancer patients". Clinical Cancer Research. 12 (1): 159–168. doi:10.1158/1078-0432.CCR-05-1340. PMID 16397038.
Yoo C, Ryu MH, Ryoo BY, Beck MY, Kang YK (October 2013). "Efficacy, safety, and pharmacokinetics of imatinib dose escalation to 800 mg/day in patients with advanced gastrointestinal stromal tumors". Investigational New Drugs. 31 (5): 1367–1374. doi:10.1007/s10637-013-9961-8. PMID 23591629. S2CID 29477955.
Demetri GD, van Oosterom AT, Garrett CR, Blackstein ME, Shah MH, Verweij J, et al. (October 2006). "Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial". Lancet. 368 (9544): 1329–1338. doi:10.1016/S0140-6736(06)69446-4. PMID 17046465. S2CID 25931515.
Herbst RS, Prager D, Hermann R, Fehrenbacher L, Johnson BE, Sandler A, et al. (September 2005). "TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer". Journal of Clinical Oncology. 23 (25): 5892–5899. doi:10.1200/JCO.2005.02.840. PMID 16043829.
Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, et al. (May 2004). "Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib" (PDF). The New England Journal of Medicine. 350 (21): 2129–2139. doi:10.1056/NEJMoa040938. PMID 15118073.
Sawyers CL (April 2008). "The cancer biomarker problem". Nature. 452 (7187): 548–552. Bibcode:2008Natur.452..548S. doi:10.1038/nature06913. PMID 18385728. S2CID 205213083.
Karas-Kuzelicki N, Mlinaric-Rascan I (August 2009). "Individualization of thiopurine therapy: thiopurine S-methyltransferase and beyond". Pharmacogenomics. 10 (8): 1309–1322. doi:10.2217/pgs.09.78. PMID 19663675.
Relling MV, Hancock ML, Rivera GK, Sandlund JT, Ribeiro RC, Krynetski EY, et al. (December 1999). "Mercaptopurine therapy intolerance and heterozygosity at the thiopurine S-methyltransferase gene locus". Journal of the National Cancer Institute. 91 (23): 2001–2008. doi:10.1093/jnci/91.23.2001. PMID 10580024.
Schneider JE, Sidhu MK, Doucet C, Kiss N, Ohsfeldt RL, Chalfin D (November 2012). "Economics of cancer biomarkers". Personalized Medicine. 9 (8): 829–837. doi:10.2217/pme.12.87. PMID 29776231.
Henze G, Dummer R, Joller-Jemelka HI, Böni R, Burg G (1997). "Serum S100--a marker for disease monitoring in metastatic melanoma". Dermatology. 194 (3): 208–212. doi:10.1159/000246103. PMID 9187834.
Harpio R, Einarsson R (July 2004). "S100 proteins as cancer biomarkers with focus on S100B in malignant melanoma". Clinical Biochemistry. 37 (7): 512–518. doi:10.1016/j.clinbiochem.2004.05.012. PMID 15234232.
Lamond NW, Skedgel C, Younis T (April 2013). "Is the 21-gene recurrence score a cost-effective assay in endocrine-sensitive node-negative breast cancer?". Expert Review of Pharmacoeconomics & Outcomes Research. 13 (2): 243–250. doi:10.1586/erp.13.4. PMID 23570435. S2CID 33661439.
Biroschak JR, Schwartz GF, Palazzo JP, Toll AD, Brill KL, Jaslow RJ, Lee SY (May 2013). "Impact of Oncotype DX on treatment decisions in ER-positive, node-negative breast cancer with histologic correlation". The Breast Journal. 19 (3): 269–275. doi:10.1111/tbj.12099. PMID 23614365. S2CID 30895945.
Moen MD, McKeage K, Plosker GL, Siddiqui MA (2007). "Imatinib: a review of its use in chronic myeloid leukaemia". Drugs. 67 (2): 299–320. doi:10.2165/00003495-200767020-00010. PMID 17284091.
Price C, McDonnell D (February 1991). "Effects of niobium filtration and constant potential on the sensitometric responses of dental radiographic films". Dento Maxillo Facial Radiology. 20 (1): 11–16. doi:10.1259/dmfr.20.1.1884846 (inactive 2024-11-28). PMID 1884846.{{cite journal}}: CS1 maint: DOI inactive as of November 2024 (link)
Cohen V, Khuri FR (2003). "Progress in lung cancer chemoprevention". Cancer Control. 10 (4): 315–324. doi:10.1177/107327480301000406. PMID 12915810.
Lu CY, Tsai HL, Uen YH, Hu HM, Chen CW, Cheng TL, et al. (March 2013). "Circulating tumor cells as a surrogate marker for determining clinical outcome to mFOLFOX chemotherapy in patients with stage III colon cancer". British Journal of Cancer. 108 (4): 791–797. doi:10.1038/bjc.2012.595. PMC 3590657. PMID 23422758.
Balic M, Williams A, Lin H, Datar R, Cote RJ (2013). "Circulating tumor cells: from bench to bedside". Annual Review of Medicine. 64: 31–44. doi:10.1146/annurev-med-050311-163404. PMC 3809995. PMID 23092385.
Madhavan D, Zucknick M, Wallwiener M, Cuk K, Modugno C, Scharpff M, et al. (November 2012). "Circulating miRNAs as surrogate markers for circulating tumor cells and prognostic markers in metastatic breast cancer". Clinical Cancer Research. 18 (21): 5972–5982. doi:10.1158/1078-0432.CCR-12-1407. PMID 22952344.
Redova M, Sana J, Slaby O (March 2013). "Circulating miRNAs as new blood-based biomarkers for solid cancers". Future Oncology. 9 (3): 387–402. doi:10.2217/fon.12.192. PMID 23469974.
Joosse SA, Pantel K (January 2013). "Biologic challenges in the detection of circulating tumor cells". Cancer Research. 73 (1): 8–11. doi:10.1158/0008-5472.CAN-12-3422. PMID 23271724.
Hou HW, Warkiani ME, Khoo BL, Li ZR, Soo RA, Tan DS, et al. (2013). "Isolation and retrieval of circulating tumor cells using centrifugal forces". Scientific Reports. 3: 1259. Bibcode:2013NatSR...3.1259H. doi:10.1038/srep01259. PMC 3569917. PMID 23405273.
Dhondt B, De Bleser E, Claeys T, Buelens S, Lumen N, Vandesompele J, et al. (December 2019). "Discovery and validation of a serum microRNA signature to characterize oligo- and polymetastatic prostate cancer: not ready for prime time". World Journal of Urology. 37 (12): 2557–2564. doi:10.1007/s00345-018-2609-8. hdl:1854/LU-8586484. PMID 30578441. S2CID 58594673.
Gonzalez RS, Carlson G, Page AJ, Cohen C (July 2011). "Gastrointestinal stromal tumor markers in cutaneous melanomas: relationship to prognostic factors and outcome". American Journal of Clinical Pathology. 136 (1): 74–80. doi:10.1309/AJCP9KHD7DCHWLMO. PMID 21685034.
Tam CS, Otero-Palacios J, Abruzzo LV, Jorgensen JL, Ferrajoli A, Wierda WG, et al. (April 2008). "Chronic lymphocytic leukaemia CD20 expression is dependent on the genetic subtype: a study of quantitative flow cytometry and fluorescent in-situ hybridization in 510 patients". British Journal of Haematology. 141 (1): 36–40. doi:10.1111/j.1365-2141.2008.07012.x. PMID 18324964.
Zhang M, Yao Z, Patel H, Garmestani K, Zhang Z, Talanov VS, et al. (May 2007). "Effective therapy of murine models of human leukemia and lymphoma with radiolabeled anti-CD30 antibody, HeFi-1". Proceedings of the National Academy of Sciences of the United States of America. 104 (20): 8444–8448. Bibcode:2007PNAS..104.8444Z. doi:10.1073/pnas.0702496104. PMC 1895969. PMID 17488826.
Yamada Y, Sanchez-Aguilera A, Brandt EB, McBride M, Al-Moamen NJ, Finkelman FD, et al. (September 2008). "FIP1L1/PDGFRalpha synergizes with SCF to induce systemic mastocytosis in a murine model of chronic eosinophilic leukemia/hypereosinophilic syndrome". Blood. 112 (6): 2500–2507. doi:10.1182/blood-2007-11-126268. PMID 18539901.
Nimer SD (May 2008). "Myelodysplastic syndromes". Blood. 111 (10): 4841–4851. doi:10.1182/blood-2007-08-078139. PMID 18467609. S2CID 6802096.
Ottmann O, Dombret H, Martinelli G, Simonsson B, Guilhot F, Larson RA, et al. (October 2007). "Dasatinib induces rapid hematologic and cytogenetic responses in adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia with resistance or intolerance to imatinib: interim results of a phase 2 study". Blood. 110 (7): 2309–2315. doi:10.1182/blood-2007-02-073528. PMID 17496201.
Boulos N, Mulder HL, Calabrese CR, Morrison JB, Rehg JE, Relling MV, et al. (March 2011). "Chemotherapeutic agents circumvent emergence of dasatinib-resistant BCR-ABL kinase mutations in a precise mouse model of Philadelphia chromosome-positive acute lymphoblastic leukemia". Blood. 117 (13): 3585–3595. doi:10.1182/blood-2010-08-301267. PMC 3072880. PMID 21263154.
O'Connell PA, Madureira PA, Berman JN, Liwski RS, Waisman DM (April 2011). "Regulation of S100A10 by the PML-RAR-α oncoprotein". Blood. 117 (15): 4095–4105. doi:10.1182/blood-2010-07-298851. PMID 21310922.
Duffy MJ, Crown J (November 2008). "A personalized approach to cancer treatment: how biomarkers can help". Clinical Chemistry. 54 (11): 1770–1779. doi:10.1373/clinchem.2008.110056. PMID 18801934.
Ribrag V, Koscielny S, Casasnovas O, Cazeneuve C, Brice P, Morschhauser F, et al. (April 2009). "Pharmacogenetic study in Hodgkin lymphomas reveals the impact of UGT1A1 polymorphisms on patient prognosis". Blood. 113 (14): 3307–3313. doi:10.1182/blood-2008-03-148874. PMID 18768784.
Li Y, Ye X, Liu J, Zha J, Pei L (January 2011). "Evaluation of EML4-ALK fusion proteins in non-small cell lung cancer using small molecule inhibitors". Neoplasia. 13 (1): 1–11. doi:10.1593/neo.101120. PMC 3022423. PMID 21245935.
Pao W, Girard N (February 2011). "New driver mutations in non-small-cell lung cancer". The Lancet. Oncology. 12 (2): 175–180. doi:10.1016/S1470-2045(10)70087-5. PMID 21277552.
Gupta D, Lis CG (October 2009). "Role of CA125 in predicting ovarian cancer survival - a review of the epidemiological literature". Journal of Ovarian Research. 2 (1): 13. doi:10.1186/1757-2215-2-13. PMC 2764643. PMID 19818123.
Bartels CL, Tsongalis GJ (April 2009). "MicroRNAs: novel biomarkers for human cancer". Clinical Chemistry. 55 (4): 623–631. doi:10.1373/clinchem.2008.112805. PMID 19246618.
Paulson KG, Lewis CW, Redman MW, Simonson WT, Lisberg A, Ritter D, et al. (April 2017). "Viral oncoprotein antibodies as a marker for recurrence of Merkel cell carcinoma: A prospective validation study". Cancer. 123 (8): 1464–1474. doi:10.1002/cncr.30475. PMC 5384867. PMID 27925665.
Proctor MJ, McMillan DC, Morrison DS, Fletcher CD, Horgan PG, Clarke SJ (August 2012). "A derived neutrophil to lymphocyte ratio predicts survival in patients with cancer". British Journal of Cancer. 107 (4): 695–699. doi:10.1038/bjc.2012.292. PMC 3419948. PMID 22828611.
Liu M, Xing LQ (August 2017). "Basic fibroblast growth factor as a potential biomarker for diagnosing malignant tumor metastasis in women". Oncology Letters. 14 (2): 1561–1567. doi:10.3892/ol.2017.6335. PMC 5529833. PMID 28789380.
Fürstenberger G, Senn HJ (May 2002). "Insulin-like growth factors and cancer". The Lancet. Oncology. 3 (5): 298–302. doi:10.1016/s1470-2045(02)00731-3. PMID 12067807.
Yu H, Rohan T (September 2000). "Role of the insulin-like growth factor family in cancer development and progression". Journal of the National Cancer Institute. 92 (18): 1472–1489. doi:10.1093/jnci/92.18.1472. PMID 10995803.
Vano YA, Oudard S, By MA, Têtu P, Thibault C, Aboudagga H, et al. (2018-04-06). "Optimal cut-off for neutrophil-to-lymphocyte ratio: Fact or Fantasy? A prospective cohort study in metastatic cancer patients". PLOS ONE. 13 (4): e0195042. Bibcode:2018PLoSO..1395042V. doi:10.1371/journal.pone.0195042. PMC 5889159. PMID 29624591.
Liu M, Xing LQ (August 2017). "Basic fibroblast growth factor as a potential biomarker for diagnosing malignant tumor metastasis in women". Oncology Letters. 14 (2): 1561–1567. doi:10.3892/ol.2017.6335. PMC 5529833. PMID 28789380.
Torrente-Rodríguez RM, Ruiz-Valdepeñas Montiel V, Campuzano S, Pedrero M, Farchado M, Vargas E, et al. (2017-04-04). "Electrochemical sensor for rapid determination of fibroblast growth factor receptor 4 in raw cancer cell lysates". PLOS ONE. 12 (4): e0175056. Bibcode:2017PLoSO..1275056T. doi:10.1371/journal.pone.0175056. PMC 5380347. PMID 28376106.
Denduluri SK, Idowu O, Wang Z, Liao Z, Yan Z, Mohammed MK, et al. (March 2015). "Insulin-like growth factor (IGF) signaling in tumorigenesis and the development of cancer drug resistance". Genes & Diseases. 2 (1): 13–25. doi:10.1016/j.gendis.2014.10.004. PMC 4431759. PMID 25984556.
Rezaei, Behzad; Majidi, Najmeh; Rahmani, Hamidreza; Khayamian, Taghi (2011). "Electrochemical impedimetric immunosensor for insulin like growth factor-1 using specific monoclonal antibody-nanogold modified electrode". Biosensors and Bioelectronics. 26 (5). Elsevier BV: 2130–2134. doi:10.1016/j.bios.2010.09.020. ISSN 0956-5663. PMID 20933383.

fda.gov

"Table of Pharmacogenomic Biomarkers in Drug Labels". U.S. Food and Drug Administration.^{[dead link]}

handle.net

hdl.handle.net

Aizpurua-Olaizola O, Toraño JS, Falcon-Perez JM, Williams C, Reichardt N, Boons GJ (2018). "Mass spectrometry for glycan biomarker discovery". TrAC Trends in Analytical Chemistry. 100: 7–14. doi:10.1016/j.trac.2017.12.015. hdl:1874/364403.
Musolino A, Bella MA, Bortesi B, Michiara M, Naldi N, Zanelli P, et al. (June 2007). "BRCA mutations, molecular markers, and clinical variables in early-onset breast cancer: a population-based study". Breast. 16 (3): 280–292. doi:10.1016/j.breast.2006.12.003. hdl:11381/1629553. PMID 17257844.
Dhondt B, De Bleser E, Claeys T, Buelens S, Lumen N, Vandesompele J, et al. (December 2019). "Discovery and validation of a serum microRNA signature to characterize oligo- and polymetastatic prostate cancer: not ready for prime time". World Journal of Urology. 37 (12): 2557–2564. doi:10.1007/s00345-018-2609-8. hdl:1854/LU-8586484. PMID 30578441. S2CID 58594673.

harvard.edu

ui.adsabs.harvard.edu

Wang Q, Chaerkady R, Wu J, Hwang HJ, Papadopoulos N, Kopelovich L, et al. (February 2011). "Mutant proteins as cancer-specific biomarkers". Proceedings of the National Academy of Sciences of the United States of America. 108 (6): 2444–2449. Bibcode:2011PNAS..108.2444W. doi:10.1073/pnas.1019203108. PMC 3038743. PMID 21248225.
Sawyers CL (April 2008). "The cancer biomarker problem". Nature. 452 (7187): 548–552. Bibcode:2008Natur.452..548S. doi:10.1038/nature06913. PMID 18385728. S2CID 205213083.
Hou HW, Warkiani ME, Khoo BL, Li ZR, Soo RA, Tan DS, et al. (2013). "Isolation and retrieval of circulating tumor cells using centrifugal forces". Scientific Reports. 3: 1259. Bibcode:2013NatSR...3.1259H. doi:10.1038/srep01259. PMC 3569917. PMID 23405273.
Zhang M, Yao Z, Patel H, Garmestani K, Zhang Z, Talanov VS, et al. (May 2007). "Effective therapy of murine models of human leukemia and lymphoma with radiolabeled anti-CD30 antibody, HeFi-1". Proceedings of the National Academy of Sciences of the United States of America. 104 (20): 8444–8448. Bibcode:2007PNAS..104.8444Z. doi:10.1073/pnas.0702496104. PMC 1895969. PMID 17488826.
Vano YA, Oudard S, By MA, Têtu P, Thibault C, Aboudagga H, et al. (2018-04-06). "Optimal cut-off for neutrophil-to-lymphocyte ratio: Fact or Fantasy? A prospective cohort study in metastatic cancer patients". PLOS ONE. 13 (4): e0195042. Bibcode:2018PLoSO..1395042V. doi:10.1371/journal.pone.0195042. PMC 5889159. PMID 29624591.
Torrente-Rodríguez RM, Ruiz-Valdepeñas Montiel V, Campuzano S, Pedrero M, Farchado M, Vargas E, et al. (2017-04-04). "Electrochemical sensor for rapid determination of fibroblast growth factor receptor 4 in raw cancer cell lysates". PLOS ONE. 12 (4): e0175056. Bibcode:2017PLoSO..1275056T. doi:10.1371/journal.pone.0175056. PMC 5380347. PMID 28376106.

mlo-online.com

Rhea J, Molinaro RJ (March 2011). "Cancer Biomarkers: Surviving the journey from bench to bedside". Medical Laboratory Observer. Archived from the original on 14 October 2013. Retrieved 26 April 2013.

nih.gov

pubmed.ncbi.nlm.nih.gov

Calzone KA (May 2012). "Genetic biomarkers of cancer risk". Seminars in Oncology Nursing. 28 (2): 122–128. doi:10.1016/j.soncn.2012.03.007. PMC 10433658. PMID 22542320.
Herceg Z, Hainaut P (June 2007). "Genetic and epigenetic alterations as biomarkers for cancer detection, diagnosis and prognosis". Molecular Oncology. 1 (1): 26–41. doi:10.1016/j.molonc.2007.01.004. PMC 5543860. PMID 19383285.
Li D, Chan DW (April 2014). "Proteomic cancer biomarkers from discovery to approval: it's worth the effort". Expert Review of Proteomics. 11 (2): 135–136. doi:10.1586/14789450.2014.897614. PMC 4079106. PMID 24646122.
Mishra A, Verma M (March 2010). "Cancer biomarkers: are we ready for the prime time?". Cancers. 2 (1): 190–208. doi:10.3390/cancers2010190. PMC 3827599. PMID 24281040.
Behne T, Copur MS (1 January 2012). "Biomarkers for hepatocellular carcinoma". International Journal of Hepatology. 2012: 859076. doi:10.1155/2012/859076. PMC 3357951. PMID 22655201.
Musolino A, Bella MA, Bortesi B, Michiara M, Naldi N, Zanelli P, et al. (June 2007). "BRCA mutations, molecular markers, and clinical variables in early-onset breast cancer: a population-based study". Breast. 16 (3): 280–292. doi:10.1016/j.breast.2006.12.003. hdl:11381/1629553. PMID 17257844.
Dienstmann R, Tabernero J (March 2011). "BRAF as a target for cancer therapy". Anti-Cancer Agents in Medicinal Chemistry. 11 (3): 285–295. doi:10.2174/187152011795347469. PMID 21426297.
Lamparella N, Barochia A, Almokadem S (2013). "Impact of Genetic Markers on Treatment of Non-small Cell Lung Cancer". Impact of Genetic Targets on Cancer Therapy. Advances in Experimental Medicine and Biology. Vol. 779. pp. 145–164. doi:10.1007/978-1-4614-6176-0_6. ISBN 978-1-4614-6175-3. PMID 23288638.
Orphanos G, Kountourakis P (2012). "Targeting the HER2 receptor in metastatic breast cancer". Hematology/Oncology and Stem Cell Therapy. 5 (3): 127–137. doi:10.5144/1658-3876.2012.127. PMID 23095788.
Deprimo SE, Huang X, Blackstein ME, Garrett CR, Harmon CS, Schöffski P, et al. (September 2009). "Circulating levels of soluble KIT serve as a biomarker for clinical outcome in gastrointestinal stromal tumor patients receiving sunitinib following imatinib failure". Clinical Cancer Research. 15 (18): 5869–5877. doi:10.1158/1078-0432.CCR-08-2480. PMC 3500590. PMID 19737953.
Bantis A, Grammaticos P (Sep–Dec 2012). "Prostatic specific antigen and bone scan in the diagnosis and follow-up of prostate cancer. Can diagnostic significance of PSA be increased?". Hellenic Journal of Nuclear Medicine. 15 (3): 241–246. PMID 23227460.
Kruijff S, Hoekstra HJ (April 2012). "The current status of S-100B as a biomarker in melanoma". European Journal of Surgical Oncology. 38 (4): 281–285. doi:10.1016/j.ejso.2011.12.005. PMID 22240030.
Ludwig JA, Weinstein JN (November 2005). "Biomarkers in cancer staging, prognosis and treatment selection". Nature Reviews. Cancer. 5 (11): 845–856. doi:10.1038/nrc1739. PMID 16239904. S2CID 25540232.
Wang Q, Chaerkady R, Wu J, Hwang HJ, Papadopoulos N, Kopelovich L, et al. (February 2011). "Mutant proteins as cancer-specific biomarkers". Proceedings of the National Academy of Sciences of the United States of America. 108 (6): 2444–2449. Bibcode:2011PNAS..108.2444W. doi:10.1073/pnas.1019203108. PMC 3038743. PMID 21248225.
Li X, Ye M, Zhang W, Tan D, Jaffrezic-Renault N, Yang X, Guo Z (February 2019). "Liquid biopsy of circulating tumor DNA and biosensor applications". Biosensors & Bioelectronics. 126: 596–607. doi:10.1016/j.bios.2018.11.037. PMID 30502682. S2CID 56479882.
Verma M, Manne U (October 2006). "Genetic and epigenetic biomarkers in cancer diagnosis and identifying high risk populations". Critical Reviews in Oncology/Hematology. 60 (1): 9–18. doi:10.1016/j.critrevonc.2006.04.002. PMID 16829121.
Leong PP, Rezai B, Koch WM, Reed A, Eisele D, Lee DJ, et al. (July 1998). "Distinguishing second primary tumors from lung metastases in patients with head and neck squamous cell carcinoma". Journal of the National Cancer Institute. 90 (13): 972–977. doi:10.1093/jnci/90.13.972. PMID 9665144.
Lapin M, Oltedal S, Tjensvoll K, Buhl T, Smaaland R, Garresori H, et al. (November 2018). "Fragment size and level of cell-free DNA provide prognostic information in patients with advanced pancreatic cancer". Journal of Translational Medicine. 16 (1): 300. doi:10.1186/s12967-018-1677-2. PMC 6218961. PMID 30400802.
Dragani TA, Matarese V, Colombo F (April 2020). "Biomarkers for Early Cancer Diagnosis: Prospects for Success through the Lens of Tumor Genetics". BioEssays. 42 (4): e1900122. doi:10.1002/bies.201900122. PMID 32128843. S2CID 212406467.
Terpos E, Dimopoulos MA, Shrivastava V, Leitzel K, Christoulas D, Migkou M, et al. (March 2010). "High levels of serum TIMP-1 correlate with advanced disease and predict for poor survival in patients with multiple myeloma treated with novel agents". Leukemia Research. 34 (3): 399–402. doi:10.1016/j.leukres.2009.08.035. PMID 19781774.
Kuukasjärvi T, Kononen J, Helin H, Holli K, Isola J (September 1996). "Loss of estrogen receptor in recurrent breast cancer is associated with poor response to endocrine therapy". Journal of Clinical Oncology. 14 (9): 2584–2589. doi:10.1200/jco.1996.14.9.2584. PMID 8823339.
Harris L, Fritsche H, Mennel R, Norton L, Ravdin P, Taube S, et al. (November 2007). "American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer". Journal of Clinical Oncology. 25 (33): 5287–5312. doi:10.1200/JCO.2007.14.2364. PMID 17954709.
Kröger N, Milde-Langosch K, Riethdorf S, Schmoor C, Schumacher M, Zander AR, Löning T (January 2006). "Prognostic and predictive effects of immunohistochemical factors in high-risk primary breast cancer patients". Clinical Cancer Research. 12 (1): 159–168. doi:10.1158/1078-0432.CCR-05-1340. PMID 16397038.
Vrbic S, Pejcic I, Filipovic S, Kocic B, Vrbic M (Jan–Mar 2013). "Current and future anti-HER2 therapy in breast cancer". Journal of B.U.On. 18 (1): 4–16. PMID 23613383.
Yoo C, Ryu MH, Ryoo BY, Beck MY, Kang YK (October 2013). "Efficacy, safety, and pharmacokinetics of imatinib dose escalation to 800 mg/day in patients with advanced gastrointestinal stromal tumors". Investigational New Drugs. 31 (5): 1367–1374. doi:10.1007/s10637-013-9961-8. PMID 23591629. S2CID 29477955.
Demetri GD, van Oosterom AT, Garrett CR, Blackstein ME, Shah MH, Verweij J, et al. (October 2006). "Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial". Lancet. 368 (9544): 1329–1338. doi:10.1016/S0140-6736(06)69446-4. PMID 17046465. S2CID 25931515.
Herbst RS, Prager D, Hermann R, Fehrenbacher L, Johnson BE, Sandler A, et al. (September 2005). "TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer". Journal of Clinical Oncology. 23 (25): 5892–5899. doi:10.1200/JCO.2005.02.840. PMID 16043829.
Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, et al. (May 2004). "Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib" (PDF). The New England Journal of Medicine. 350 (21): 2129–2139. doi:10.1056/NEJMoa040938. PMID 15118073.
Sawyers CL (April 2008). "The cancer biomarker problem". Nature. 452 (7187): 548–552. Bibcode:2008Natur.452..548S. doi:10.1038/nature06913. PMID 18385728. S2CID 205213083.
Karas-Kuzelicki N, Mlinaric-Rascan I (August 2009). "Individualization of thiopurine therapy: thiopurine S-methyltransferase and beyond". Pharmacogenomics. 10 (8): 1309–1322. doi:10.2217/pgs.09.78. PMID 19663675.
Relling MV, Hancock ML, Rivera GK, Sandlund JT, Ribeiro RC, Krynetski EY, et al. (December 1999). "Mercaptopurine therapy intolerance and heterozygosity at the thiopurine S-methyltransferase gene locus". Journal of the National Cancer Institute. 91 (23): 2001–2008. doi:10.1093/jnci/91.23.2001. PMID 10580024.
Schneider JE, Sidhu MK, Doucet C, Kiss N, Ohsfeldt RL, Chalfin D (November 2012). "Economics of cancer biomarkers". Personalized Medicine. 9 (8): 829–837. doi:10.2217/pme.12.87. PMID 29776231.
Henze G, Dummer R, Joller-Jemelka HI, Böni R, Burg G (1997). "Serum S100--a marker for disease monitoring in metastatic melanoma". Dermatology. 194 (3): 208–212. doi:10.1159/000246103. PMID 9187834.
Harpio R, Einarsson R (July 2004). "S100 proteins as cancer biomarkers with focus on S100B in malignant melanoma". Clinical Biochemistry. 37 (7): 512–518. doi:10.1016/j.clinbiochem.2004.05.012. PMID 15234232.
Lamond NW, Skedgel C, Younis T (April 2013). "Is the 21-gene recurrence score a cost-effective assay in endocrine-sensitive node-negative breast cancer?". Expert Review of Pharmacoeconomics & Outcomes Research. 13 (2): 243–250. doi:10.1586/erp.13.4. PMID 23570435. S2CID 33661439.
Biroschak JR, Schwartz GF, Palazzo JP, Toll AD, Brill KL, Jaslow RJ, Lee SY (May 2013). "Impact of Oncotype DX on treatment decisions in ER-positive, node-negative breast cancer with histologic correlation". The Breast Journal. 19 (3): 269–275. doi:10.1111/tbj.12099. PMID 23614365. S2CID 30895945.
Moen MD, McKeage K, Plosker GL, Siddiqui MA (2007). "Imatinib: a review of its use in chronic myeloid leukaemia". Drugs. 67 (2): 299–320. doi:10.2165/00003495-200767020-00010. PMID 17284091.
Price C, McDonnell D (February 1991). "Effects of niobium filtration and constant potential on the sensitometric responses of dental radiographic films". Dento Maxillo Facial Radiology. 20 (1): 11–16. doi:10.1259/dmfr.20.1.1884846 (inactive 2024-11-28). PMID 1884846.{{cite journal}}: CS1 maint: DOI inactive as of November 2024 (link)
Cohen V, Khuri FR (2003). "Progress in lung cancer chemoprevention". Cancer Control. 10 (4): 315–324. doi:10.1177/107327480301000406. PMID 12915810.
Lu CY, Tsai HL, Uen YH, Hu HM, Chen CW, Cheng TL, et al. (March 2013). "Circulating tumor cells as a surrogate marker for determining clinical outcome to mFOLFOX chemotherapy in patients with stage III colon cancer". British Journal of Cancer. 108 (4): 791–797. doi:10.1038/bjc.2012.595. PMC 3590657. PMID 23422758.
Balic M, Williams A, Lin H, Datar R, Cote RJ (2013). "Circulating tumor cells: from bench to bedside". Annual Review of Medicine. 64: 31–44. doi:10.1146/annurev-med-050311-163404. PMC 3809995. PMID 23092385.
Madhavan D, Zucknick M, Wallwiener M, Cuk K, Modugno C, Scharpff M, et al. (November 2012). "Circulating miRNAs as surrogate markers for circulating tumor cells and prognostic markers in metastatic breast cancer". Clinical Cancer Research. 18 (21): 5972–5982. doi:10.1158/1078-0432.CCR-12-1407. PMID 22952344.
Redova M, Sana J, Slaby O (March 2013). "Circulating miRNAs as new blood-based biomarkers for solid cancers". Future Oncology. 9 (3): 387–402. doi:10.2217/fon.12.192. PMID 23469974.
Joosse SA, Pantel K (January 2013). "Biologic challenges in the detection of circulating tumor cells". Cancer Research. 73 (1): 8–11. doi:10.1158/0008-5472.CAN-12-3422. PMID 23271724.
Hou HW, Warkiani ME, Khoo BL, Li ZR, Soo RA, Tan DS, et al. (2013). "Isolation and retrieval of circulating tumor cells using centrifugal forces". Scientific Reports. 3: 1259. Bibcode:2013NatSR...3.1259H. doi:10.1038/srep01259. PMC 3569917. PMID 23405273.
Dhondt B, De Bleser E, Claeys T, Buelens S, Lumen N, Vandesompele J, et al. (December 2019). "Discovery and validation of a serum microRNA signature to characterize oligo- and polymetastatic prostate cancer: not ready for prime time". World Journal of Urology. 37 (12): 2557–2564. doi:10.1007/s00345-018-2609-8. hdl:1854/LU-8586484. PMID 30578441. S2CID 58594673.
Gonzalez RS, Carlson G, Page AJ, Cohen C (July 2011). "Gastrointestinal stromal tumor markers in cutaneous melanomas: relationship to prognostic factors and outcome". American Journal of Clinical Pathology. 136 (1): 74–80. doi:10.1309/AJCP9KHD7DCHWLMO. PMID 21685034.
Tam CS, Otero-Palacios J, Abruzzo LV, Jorgensen JL, Ferrajoli A, Wierda WG, et al. (April 2008). "Chronic lymphocytic leukaemia CD20 expression is dependent on the genetic subtype: a study of quantitative flow cytometry and fluorescent in-situ hybridization in 510 patients". British Journal of Haematology. 141 (1): 36–40. doi:10.1111/j.1365-2141.2008.07012.x. PMID 18324964.
Zhang M, Yao Z, Patel H, Garmestani K, Zhang Z, Talanov VS, et al. (May 2007). "Effective therapy of murine models of human leukemia and lymphoma with radiolabeled anti-CD30 antibody, HeFi-1". Proceedings of the National Academy of Sciences of the United States of America. 104 (20): 8444–8448. Bibcode:2007PNAS..104.8444Z. doi:10.1073/pnas.0702496104. PMC 1895969. PMID 17488826.
Yamada Y, Sanchez-Aguilera A, Brandt EB, McBride M, Al-Moamen NJ, Finkelman FD, et al. (September 2008). "FIP1L1/PDGFRalpha synergizes with SCF to induce systemic mastocytosis in a murine model of chronic eosinophilic leukemia/hypereosinophilic syndrome". Blood. 112 (6): 2500–2507. doi:10.1182/blood-2007-11-126268. PMID 18539901.
Nimer SD (May 2008). "Myelodysplastic syndromes". Blood. 111 (10): 4841–4851. doi:10.1182/blood-2007-08-078139. PMID 18467609. S2CID 6802096.
Ottmann O, Dombret H, Martinelli G, Simonsson B, Guilhot F, Larson RA, et al. (October 2007). "Dasatinib induces rapid hematologic and cytogenetic responses in adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia with resistance or intolerance to imatinib: interim results of a phase 2 study". Blood. 110 (7): 2309–2315. doi:10.1182/blood-2007-02-073528. PMID 17496201.
Boulos N, Mulder HL, Calabrese CR, Morrison JB, Rehg JE, Relling MV, et al. (March 2011). "Chemotherapeutic agents circumvent emergence of dasatinib-resistant BCR-ABL kinase mutations in a precise mouse model of Philadelphia chromosome-positive acute lymphoblastic leukemia". Blood. 117 (13): 3585–3595. doi:10.1182/blood-2010-08-301267. PMC 3072880. PMID 21263154.
O'Connell PA, Madureira PA, Berman JN, Liwski RS, Waisman DM (April 2011). "Regulation of S100A10 by the PML-RAR-α oncoprotein". Blood. 117 (15): 4095–4105. doi:10.1182/blood-2010-07-298851. PMID 21310922.
Duffy MJ, Crown J (November 2008). "A personalized approach to cancer treatment: how biomarkers can help". Clinical Chemistry. 54 (11): 1770–1779. doi:10.1373/clinchem.2008.110056. PMID 18801934.
Ribrag V, Koscielny S, Casasnovas O, Cazeneuve C, Brice P, Morschhauser F, et al. (April 2009). "Pharmacogenetic study in Hodgkin lymphomas reveals the impact of UGT1A1 polymorphisms on patient prognosis". Blood. 113 (14): 3307–3313. doi:10.1182/blood-2008-03-148874. PMID 18768784.
Li Y, Ye X, Liu J, Zha J, Pei L (January 2011). "Evaluation of EML4-ALK fusion proteins in non-small cell lung cancer using small molecule inhibitors". Neoplasia. 13 (1): 1–11. doi:10.1593/neo.101120. PMC 3022423. PMID 21245935.
Pao W, Girard N (February 2011). "New driver mutations in non-small-cell lung cancer". The Lancet. Oncology. 12 (2): 175–180. doi:10.1016/S1470-2045(10)70087-5. PMID 21277552.
Gupta D, Lis CG (October 2009). "Role of CA125 in predicting ovarian cancer survival - a review of the epidemiological literature". Journal of Ovarian Research. 2 (1): 13. doi:10.1186/1757-2215-2-13. PMC 2764643. PMID 19818123.
Bartels CL, Tsongalis GJ (April 2009). "MicroRNAs: novel biomarkers for human cancer". Clinical Chemistry. 55 (4): 623–631. doi:10.1373/clinchem.2008.112805. PMID 19246618.
Paulson KG, Lewis CW, Redman MW, Simonson WT, Lisberg A, Ritter D, et al. (April 2017). "Viral oncoprotein antibodies as a marker for recurrence of Merkel cell carcinoma: A prospective validation study". Cancer. 123 (8): 1464–1474. doi:10.1002/cncr.30475. PMC 5384867. PMID 27925665.
Proctor MJ, McMillan DC, Morrison DS, Fletcher CD, Horgan PG, Clarke SJ (August 2012). "A derived neutrophil to lymphocyte ratio predicts survival in patients with cancer". British Journal of Cancer. 107 (4): 695–699. doi:10.1038/bjc.2012.292. PMC 3419948. PMID 22828611.
Liu M, Xing LQ (August 2017). "Basic fibroblast growth factor as a potential biomarker for diagnosing malignant tumor metastasis in women". Oncology Letters. 14 (2): 1561–1567. doi:10.3892/ol.2017.6335. PMC 5529833. PMID 28789380.
Fürstenberger G, Senn HJ (May 2002). "Insulin-like growth factors and cancer". The Lancet. Oncology. 3 (5): 298–302. doi:10.1016/s1470-2045(02)00731-3. PMID 12067807.
Yu H, Rohan T (September 2000). "Role of the insulin-like growth factor family in cancer development and progression". Journal of the National Cancer Institute. 92 (18): 1472–1489. doi:10.1093/jnci/92.18.1472. PMID 10995803.
Vano YA, Oudard S, By MA, Têtu P, Thibault C, Aboudagga H, et al. (2018-04-06). "Optimal cut-off for neutrophil-to-lymphocyte ratio: Fact or Fantasy? A prospective cohort study in metastatic cancer patients". PLOS ONE. 13 (4): e0195042. Bibcode:2018PLoSO..1395042V. doi:10.1371/journal.pone.0195042. PMC 5889159. PMID 29624591.
Liu M, Xing LQ (August 2017). "Basic fibroblast growth factor as a potential biomarker for diagnosing malignant tumor metastasis in women". Oncology Letters. 14 (2): 1561–1567. doi:10.3892/ol.2017.6335. PMC 5529833. PMID 28789380.
Torrente-Rodríguez RM, Ruiz-Valdepeñas Montiel V, Campuzano S, Pedrero M, Farchado M, Vargas E, et al. (2017-04-04). "Electrochemical sensor for rapid determination of fibroblast growth factor receptor 4 in raw cancer cell lysates". PLOS ONE. 12 (4): e0175056. Bibcode:2017PLoSO..1275056T. doi:10.1371/journal.pone.0175056. PMC 5380347. PMID 28376106.
Denduluri SK, Idowu O, Wang Z, Liao Z, Yan Z, Mohammed MK, et al. (March 2015). "Insulin-like growth factor (IGF) signaling in tumorigenesis and the development of cancer drug resistance". Genes & Diseases. 2 (1): 13–25. doi:10.1016/j.gendis.2014.10.004. PMC 4431759. PMID 25984556.
Rezaei, Behzad; Majidi, Najmeh; Rahmani, Hamidreza; Khayamian, Taghi (2011). "Electrochemical impedimetric immunosensor for insulin like growth factor-1 using specific monoclonal antibody-nanogold modified electrode". Biosensors and Bioelectronics. 26 (5). Elsevier BV: 2130–2134. doi:10.1016/j.bios.2010.09.020. ISSN 0956-5663. PMID 20933383.

ncbi.nlm.nih.gov

Calzone KA (May 2012). "Genetic biomarkers of cancer risk". Seminars in Oncology Nursing. 28 (2): 122–128. doi:10.1016/j.soncn.2012.03.007. PMC 10433658. PMID 22542320.
Herceg Z, Hainaut P (June 2007). "Genetic and epigenetic alterations as biomarkers for cancer detection, diagnosis and prognosis". Molecular Oncology. 1 (1): 26–41. doi:10.1016/j.molonc.2007.01.004. PMC 5543860. PMID 19383285.
Li D, Chan DW (April 2014). "Proteomic cancer biomarkers from discovery to approval: it's worth the effort". Expert Review of Proteomics. 11 (2): 135–136. doi:10.1586/14789450.2014.897614. PMC 4079106. PMID 24646122.
Mishra A, Verma M (March 2010). "Cancer biomarkers: are we ready for the prime time?". Cancers. 2 (1): 190–208. doi:10.3390/cancers2010190. PMC 3827599. PMID 24281040.
Behne T, Copur MS (1 January 2012). "Biomarkers for hepatocellular carcinoma". International Journal of Hepatology. 2012: 859076. doi:10.1155/2012/859076. PMC 3357951. PMID 22655201.
Deprimo SE, Huang X, Blackstein ME, Garrett CR, Harmon CS, Schöffski P, et al. (September 2009). "Circulating levels of soluble KIT serve as a biomarker for clinical outcome in gastrointestinal stromal tumor patients receiving sunitinib following imatinib failure". Clinical Cancer Research. 15 (18): 5869–5877. doi:10.1158/1078-0432.CCR-08-2480. PMC 3500590. PMID 19737953.
Wang Q, Chaerkady R, Wu J, Hwang HJ, Papadopoulos N, Kopelovich L, et al. (February 2011). "Mutant proteins as cancer-specific biomarkers". Proceedings of the National Academy of Sciences of the United States of America. 108 (6): 2444–2449. Bibcode:2011PNAS..108.2444W. doi:10.1073/pnas.1019203108. PMC 3038743. PMID 21248225.
Lapin M, Oltedal S, Tjensvoll K, Buhl T, Smaaland R, Garresori H, et al. (November 2018). "Fragment size and level of cell-free DNA provide prognostic information in patients with advanced pancreatic cancer". Journal of Translational Medicine. 16 (1): 300. doi:10.1186/s12967-018-1677-2. PMC 6218961. PMID 30400802.
Lu CY, Tsai HL, Uen YH, Hu HM, Chen CW, Cheng TL, et al. (March 2013). "Circulating tumor cells as a surrogate marker for determining clinical outcome to mFOLFOX chemotherapy in patients with stage III colon cancer". British Journal of Cancer. 108 (4): 791–797. doi:10.1038/bjc.2012.595. PMC 3590657. PMID 23422758.
Balic M, Williams A, Lin H, Datar R, Cote RJ (2013). "Circulating tumor cells: from bench to bedside". Annual Review of Medicine. 64: 31–44. doi:10.1146/annurev-med-050311-163404. PMC 3809995. PMID 23092385.
Hou HW, Warkiani ME, Khoo BL, Li ZR, Soo RA, Tan DS, et al. (2013). "Isolation and retrieval of circulating tumor cells using centrifugal forces". Scientific Reports. 3: 1259. Bibcode:2013NatSR...3.1259H. doi:10.1038/srep01259. PMC 3569917. PMID 23405273.
Zhang M, Yao Z, Patel H, Garmestani K, Zhang Z, Talanov VS, et al. (May 2007). "Effective therapy of murine models of human leukemia and lymphoma with radiolabeled anti-CD30 antibody, HeFi-1". Proceedings of the National Academy of Sciences of the United States of America. 104 (20): 8444–8448. Bibcode:2007PNAS..104.8444Z. doi:10.1073/pnas.0702496104. PMC 1895969. PMID 17488826.
Boulos N, Mulder HL, Calabrese CR, Morrison JB, Rehg JE, Relling MV, et al. (March 2011). "Chemotherapeutic agents circumvent emergence of dasatinib-resistant BCR-ABL kinase mutations in a precise mouse model of Philadelphia chromosome-positive acute lymphoblastic leukemia". Blood. 117 (13): 3585–3595. doi:10.1182/blood-2010-08-301267. PMC 3072880. PMID 21263154.
Li Y, Ye X, Liu J, Zha J, Pei L (January 2011). "Evaluation of EML4-ALK fusion proteins in non-small cell lung cancer using small molecule inhibitors". Neoplasia. 13 (1): 1–11. doi:10.1593/neo.101120. PMC 3022423. PMID 21245935.
Gupta D, Lis CG (October 2009). "Role of CA125 in predicting ovarian cancer survival - a review of the epidemiological literature". Journal of Ovarian Research. 2 (1): 13. doi:10.1186/1757-2215-2-13. PMC 2764643. PMID 19818123.
Paulson KG, Lewis CW, Redman MW, Simonson WT, Lisberg A, Ritter D, et al. (April 2017). "Viral oncoprotein antibodies as a marker for recurrence of Merkel cell carcinoma: A prospective validation study". Cancer. 123 (8): 1464–1474. doi:10.1002/cncr.30475. PMC 5384867. PMID 27925665.
Proctor MJ, McMillan DC, Morrison DS, Fletcher CD, Horgan PG, Clarke SJ (August 2012). "A derived neutrophil to lymphocyte ratio predicts survival in patients with cancer". British Journal of Cancer. 107 (4): 695–699. doi:10.1038/bjc.2012.292. PMC 3419948. PMID 22828611.
Liu M, Xing LQ (August 2017). "Basic fibroblast growth factor as a potential biomarker for diagnosing malignant tumor metastasis in women". Oncology Letters. 14 (2): 1561–1567. doi:10.3892/ol.2017.6335. PMC 5529833. PMID 28789380.
Vano YA, Oudard S, By MA, Têtu P, Thibault C, Aboudagga H, et al. (2018-04-06). "Optimal cut-off for neutrophil-to-lymphocyte ratio: Fact or Fantasy? A prospective cohort study in metastatic cancer patients". PLOS ONE. 13 (4): e0195042. Bibcode:2018PLoSO..1395042V. doi:10.1371/journal.pone.0195042. PMC 5889159. PMID 29624591.
Liu M, Xing LQ (August 2017). "Basic fibroblast growth factor as a potential biomarker for diagnosing malignant tumor metastasis in women". Oncology Letters. 14 (2): 1561–1567. doi:10.3892/ol.2017.6335. PMC 5529833. PMID 28789380.
Torrente-Rodríguez RM, Ruiz-Valdepeñas Montiel V, Campuzano S, Pedrero M, Farchado M, Vargas E, et al. (2017-04-04). "Electrochemical sensor for rapid determination of fibroblast growth factor receptor 4 in raw cancer cell lysates". PLOS ONE. 12 (4): e0175056. Bibcode:2017PLoSO..1275056T. doi:10.1371/journal.pone.0175056. PMC 5380347. PMID 28376106.
Denduluri SK, Idowu O, Wang Z, Liao Z, Yan Z, Mohammed MK, et al. (March 2015). "Insulin-like growth factor (IGF) signaling in tumorigenesis and the development of cancer drug resistance". Genes & Diseases. 2 (1): 13–25. doi:10.1016/j.gendis.2014.10.004. PMC 4431759. PMID 25984556.

researchadvocacy.org

"Biomarkers in Cancer: An Introductory Guide for Advocates" (PDF). Research Advocacy Network. 2010. Archived from the original (PDF) on 2013-10-29. Retrieved 26 April 2013.

semanticscholar.org

api.semanticscholar.org

Ludwig JA, Weinstein JN (November 2005). "Biomarkers in cancer staging, prognosis and treatment selection". Nature Reviews. Cancer. 5 (11): 845–856. doi:10.1038/nrc1739. PMID 16239904. S2CID 25540232.
Li X, Ye M, Zhang W, Tan D, Jaffrezic-Renault N, Yang X, Guo Z (February 2019). "Liquid biopsy of circulating tumor DNA and biosensor applications". Biosensors & Bioelectronics. 126: 596–607. doi:10.1016/j.bios.2018.11.037. PMID 30502682. S2CID 56479882.
Dragani TA, Matarese V, Colombo F (April 2020). "Biomarkers for Early Cancer Diagnosis: Prospects for Success through the Lens of Tumor Genetics". BioEssays. 42 (4): e1900122. doi:10.1002/bies.201900122. PMID 32128843. S2CID 212406467.
Yoo C, Ryu MH, Ryoo BY, Beck MY, Kang YK (October 2013). "Efficacy, safety, and pharmacokinetics of imatinib dose escalation to 800 mg/day in patients with advanced gastrointestinal stromal tumors". Investigational New Drugs. 31 (5): 1367–1374. doi:10.1007/s10637-013-9961-8. PMID 23591629. S2CID 29477955.
Demetri GD, van Oosterom AT, Garrett CR, Blackstein ME, Shah MH, Verweij J, et al. (October 2006). "Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial". Lancet. 368 (9544): 1329–1338. doi:10.1016/S0140-6736(06)69446-4. PMID 17046465. S2CID 25931515.
Sawyers CL (April 2008). "The cancer biomarker problem". Nature. 452 (7187): 548–552. Bibcode:2008Natur.452..548S. doi:10.1038/nature06913. PMID 18385728. S2CID 205213083.
Lamond NW, Skedgel C, Younis T (April 2013). "Is the 21-gene recurrence score a cost-effective assay in endocrine-sensitive node-negative breast cancer?". Expert Review of Pharmacoeconomics & Outcomes Research. 13 (2): 243–250. doi:10.1586/erp.13.4. PMID 23570435. S2CID 33661439.
Biroschak JR, Schwartz GF, Palazzo JP, Toll AD, Brill KL, Jaslow RJ, Lee SY (May 2013). "Impact of Oncotype DX on treatment decisions in ER-positive, node-negative breast cancer with histologic correlation". The Breast Journal. 19 (3): 269–275. doi:10.1111/tbj.12099. PMID 23614365. S2CID 30895945.
Dhondt B, De Bleser E, Claeys T, Buelens S, Lumen N, Vandesompele J, et al. (December 2019). "Discovery and validation of a serum microRNA signature to characterize oligo- and polymetastatic prostate cancer: not ready for prime time". World Journal of Urology. 37 (12): 2557–2564. doi:10.1007/s00345-018-2609-8. hdl:1854/LU-8586484. PMID 30578441. S2CID 58594673.
Nimer SD (May 2008). "Myelodysplastic syndromes". Blood. 111 (10): 4841–4851. doi:10.1182/blood-2007-08-078139. PMID 18467609. S2CID 6802096.

singularityhub.com

Hewes A (October 2, 2014). "Promising Method for Detecting Pancreatic Cancer Years Before Traditional Diagnosis". Singularity HUB. Retrieved 2016-04-22.

time.com

Lemonick M, Park A (May 28, 2001). "New Hope for Cancer". Time. Archived from the original on October 15, 2007. Retrieved 26 April 2013.

web.archive.org

Rhea J, Molinaro RJ (March 2011). "Cancer Biomarkers: Surviving the journey from bench to bedside". Medical Laboratory Observer. Archived from the original on 14 October 2013. Retrieved 26 April 2013.
"Biomarkers in Cancer: An Introductory Guide for Advocates" (PDF). Research Advocacy Network. 2010. Archived from the original (PDF) on 2013-10-29. Retrieved 26 April 2013.
Lemonick M, Park A (May 28, 2001). "New Hope for Cancer". Time. Archived from the original on October 15, 2007. Retrieved 26 April 2013.

worldcat.org

search.worldcat.org

Rezaei, Behzad; Majidi, Najmeh; Rahmani, Hamidreza; Khayamian, Taghi (2011). "Electrochemical impedimetric immunosensor for insulin like growth factor-1 using specific monoclonal antibody-nanogold modified electrode". Biosensors and Bioelectronics. 26 (5). Elsevier BV: 2130–2134. doi:10.1016/j.bios.2010.09.020. ISSN 0956-5663. PMID 20933383.

zenodo.org

Ludwig JA, Weinstein JN (November 2005). "Biomarkers in cancer staging, prognosis and treatment selection". Nature Reviews. Cancer. 5 (11): 845–856. doi:10.1038/nrc1739. PMID 16239904. S2CID 25540232.
Verma M, Manne U (October 2006). "Genetic and epigenetic biomarkers in cancer diagnosis and identifying high risk populations". Critical Reviews in Oncology/Hematology. 60 (1): 9–18. doi:10.1016/j.critrevonc.2006.04.002. PMID 16829121.